| [1] Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N, Mühlemann O. Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci, 2010, 67(5): 677-700.[2] Losson R, Lacroute F. Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc Natl Acad Sci USA, 1979, 76(10): 5134-5137.[3] Maquat LE, Kinniburgh AJ, Rachimilewiz EA, Ross J. Unstable beta-globin mRNA in mRNA-deficient beta (0) thalassemia. Cell, 1981, 27(3 Pt 2): 543-553.[4] Bhuvanagiri M, Schlitter AM, Hentze MW, Kulozik AE. NMD: RNA biology meets human genetic medicine. Biochem J, 2010, 430(3): 365-377.[5] Culbertson MR. RNA surveillance. Unforeseen conse-quences for gene expression, inherited genetic disorders and cancer. Trends Genet, 1999, 15(2): 74-80.[6] Franks TM, Singh G, Lykke-Andersen J. Upf1 ATPase-dependent mRNP disassembly is required for completion of nonsense-mediated mRNA decay. Cell, 2010, 143(6): 938-950.[7] Durand S, Lykke-Andersen J. SnapShot: nonsense-mediated mRNA decay. Cell, 2011, 145(2): 324.[8] Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Bio-chem, 2007, 76(1): 51-74.[9] Hwang J, Maquat LE. Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the question. Curr Opin Genet Dev, 2011, 21(4): 422-430.[10] Maquat LE, Tarn WY, Isken O. The pioneer round of translation: features and functions. Cell, 2010, 142(3): 368-374.[11] Kadlec J, Izaurralde E, Cusack S. The structural basis for the interaction between nonsense-mediated mRNA decay factors UPF2 and UPF3. Nat Struct Mol Biol, 2004, 11(4): 330-337.[12] Gehring NH, Lamprinaki S, Hentze MW, Kulozik AE, Misteli T. The hierarchy of exon-junction complex assembly by the spliceosome explains key features of mammalian nonsense-mediated mRNA decay. PLoS Biol, 2009, 7(5): e1000120.[13] Wang J, Gudikote JP, Olivas OR, Wilkinson MF. Bound-ary-independent polar nonsense-mediated decay. EMBO Rep, 2002, 3(3): 274-279.[14] Cusack BP, Arndt PF, Duret L, Roest Crollius H, Zhang J Z. Preventing dangerous nonsense: selection for robust-ness to transcriptional error in human genes. PLoS Genet, 2011, 7(10): e1002276.[15] Rebbapragada I, Lykke-Andersen J. Execution of non-sense-mediated mRNA decay: what defines a substrate? Curr Opin Cell Biol, 2009, 21(3): 394-402.[16] Hogg JR, Goff SP. Upf1 senses 3’UTR length to potentiate mRNA decay. Cell, 2010, 143(3): 379-389.[17] Bühler M, Steiner S, Mohn F, Paillusson A, Mühlemann O. EJC-independent degradation of nonsense immunoglobu-lin-mu mRNA depends on 3' UTR length. Nat Struct Mol Biol, 2006, 13(5): 462-464.[18] Wen J, Brogna S. Splicing-dependent NMD does not require the EJC in Schizosaccharomyces pombe. EMBO J, 2010, 29(9): 1537-1551.[19] Forget BG, Benz EJ Jr, Skoultchi A, Baglioni C, Housman D. Absence of messenger RNA for beta globin chain in β0 thalassaemia. Nature, 1974, 247(440): 379-381.[20] Baserga SJ, Benz EJ Jr. Nonsense mutations in the human beta-globin gene affect mRNA metabolism. Pro Natl Acad Sci USA, 1988, 85(7): 2056-2060.[21] Hall GW, Thein S. Nonesense codon mutations in the terminal exon of the β-mRNA accumulation: a mechanism for the phenotype of dominant β-thalassemia. Blood, 1994, 83(8): 2031-2037.[22] Gerards M, van den Bosch B, Calis C, Schoonderwoerd K, van Engelen K, Tijssen M, de Coo R, van der Kooi A, Smeets H. Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy. Mito-chondrion, 2010, 10(5): 510-515.[23] Isidor B, Lindenbaum P, Pichon O, Stéphane Bézieau, Dina C, Jacquemont S, Martin-Coignard D, Thau-vin-Robinet C, Le Merrer M, Mandel JL, David A, Faivre L, Cormier-Daire V, Redon R, Le Caignec C. Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat Genet, 2011, 43(4): 306-308.[24] Holbrook JA, NeuYilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay approaches the clinic. Nat Genet, 2004, 36(8): 801-808.[25] Khajavi M, Inoue K, Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet, 2006, 14(10): 1074-1081.[26] Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, Mancias P, Butler IJ, Wilkinson MF, Wegner M, Lupski JR. Molecular mechanism for distinct neuro-logical phenotypes conveyed by allelic truncating mutations. Nat Genet, 2004, 36(4): 361-369.[27] Kerr TP, Sewry CA, Robb SA, Roberts RG. Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay? Hum Genet, 2001, 109(4): 402-407.[28] Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Hamida M, Pericak-Vance M, Hentati F, Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet, 2001, 29(2): 160-165.[29] Gros-Louis F, Meijer IA, Hand CK, Dubé MP, MacGregor DL, Seni MH, Devon RS, Hayden MR, Andermann F, Andermann E, Rouleau GA. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann Neurol, 2003, 53(1): 144-145.[30] Pusch M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum Mutat, 2002, 19(4): 423-434.[31] 徐汪洋, 孙莲花, 顾鸣敏. 腓骨肌萎缩症的遗传特征及致病机制的研究进展. 国际遗传学杂志, 2010, 33(2): 93-96.[32] Nosensie EN, Diez HC. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol, 2001, 19(5): 434-439.[33] Paillusson A, Hirschi N, Vallan C, Azzalin CM, Mühlemann O. A GFP-based reporter system to monitor nonsense-mediated mRNA decay. Nucleic Acids Res, 2005, 33(6): e54.[34] Garagiola I, Valsecchi C, Lavoretano S, Oren H, Bohm M, Peyvandi F. Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion. Haematologica, 2008, 93(11): 1678-1685.[35] Mendell JT, ap Rhys CMJ, Dietz HC. Separable roles for rent1/hUpf1 in altered splicing and decay of nonsense transcripts. Science, 2002, 298(5592): 419-421.[36] Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Cell, 2008, 24(11): 552-563.[37] Karijolich J, Yu YT. Converting nonsense codons into sense codons by targeted pseudouridylation. Nature, 2011, 474(7351): 395-399.[38] Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne muscular dystro-phy. Curr Opin Neurol, 2009, 22(5): 532-538. |
